De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Fujian Wanchen Biotechnology Group Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Li Qing Wang

Algemeen directeur

CN¥867.4k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	1.1yrs

Recente managementupdates

Recent updates

Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company

Oct 01

Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing

Sep 30

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Aug 04

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Jun 06

CEO

Li Qing Wang (59 yo)

no data

Tenure

CN¥867,400

Compensatie

Ms. Li Qing Wang is GM & Director of Fujian Wanchen Biotechnology Co., Ltd.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Li Qing Wang	GM & Director	no data	CN¥867.40k	0.10% CN¥ 7.4m
Zening Wang	Deputy GM & Director	no data	CN¥271.10k	14.27% CN¥ 1.0b
Bo Li	Deputy GM & Director	no data	CN¥609.70k	0.017% CN¥ 1.2m
Jian Kun Wang	Chairman of the Board	no data	CN¥787.40k	0.20% CN¥ 14.7m
Wen Zhu Chen	Director	no data	CN¥120.00k	geen gegevens
Gai Chun Lin	Non-Independent Director	1.1yrs	CN¥120.00k	0.067% CN¥ 4.9m
Qing Liang Cai	Independent Director	no data	CN¥96.00k	geen gegevens
Liye Lin	Independent Director	1.1yrs	CN¥57.50k	geen gegevens
Jingwen Zhao	Independent Director	1.1yrs	CN¥26.40k	geen gegevens
Yiyong Chen	Chairman of the Supervisory Board	1.1yrs	geen gegevens	geen gegevens
Jianlin Yao	Non-Employee Supervisor	1.1yrs	geen gegevens	geen gegevens

1.1yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300972 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw bestuur.

Fujian Wanchen Biotechnology Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024

Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments

Less than half of directors are independent

Recent updates

Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing

New major risk - Share price stability

Price target increased by 11% to CN¥31.66

Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.38 loss in 2Q 2023)

New minor risk - Share price stability

Now 21% overvalued

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Fujian Wanchen Biotechnology Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Less than half of directors are independent

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024

Price target decreased by 27% to CN¥28.54

New minor risk - Shareholder dilution

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.33 loss per share (vs CN¥0.23 profit in 3Q 2022)

Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments

New major risk - Earnings quality

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.15 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Fujian Wanchen Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.16 in 1Q 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.063 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.18 loss in 2Q 2021)

Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022

Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021

Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.17 (vs CN¥0.84 in FY 2020)

Third quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.20 profit in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.03 loss in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.22 in 1Q 2020)

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd